The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1525324
Carcinoembryonic Antigen Trajectory Predicts Pathological Complete Response in Advanced Gastric Cancer after Neoadjuvant Chemotherapy
Provisionally accepted- 1 The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 2 Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China
- 3 Sun Yat-sen University, Guangzhou, Guangdong Province, China
Aims: This study aims to develop a simple, clinically applicable classification system to predict pCR based on carcinoembryonic antigen (CEA) trajectory during NAC. Methods: This study included 366 AGC patients who received NAC followed by radical gastrectomy. CEA levels were measured before, during, and after NAC, with changes classified into three trajectory types: Type I (>=80% decline), Type II (>=40% but <80% decline), and Type III (<40% decline or increase). We analyzed associations between these CEA trajectories, pCR, lymph node remission, and survival. Results: pCR was achieved in 10.4% (38/366) of patients. pCR rates were significantly higher in Type I (41%) and Type II (15.8%) trajectories compared to Type III (6.7%). Lymph node remission also correlated with CEA trajectories, with Type I having the highest proportion of ypN0 (79.2%). Multivariate analysis identified CEA trajectory subtypes and tumor differentiation as independent predictors of pCR. This classification system proved robust across subgroups. Although no significant differences in overall survival were observed between subtypes, higher initial CEA levels were associated with worse survival. Conclusion: The trajectory of CEA change during NAC is a promising predictor of pCR in AGC. This simple and accessible classification system may facilitate personalized surgical strategies for patients with AGC.
Keywords: gastric cancer, Carcinoembryonic Antigen, Trajectory analysis (TA), Pathological complete response, Neoadjuvant chemotherapy
Received: 09 Nov 2024; Accepted: 22 Jan 2025.
Copyright: © 2025 Chen, Liu, Wei, Lin, Wang, Sun, Wang, Peng and Lian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yonghe Chen, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Lei Lian, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.